ライフサイエンスコーパス: cannabinoid receptor agonist

1 le with that observed previously with potent cannabinoid receptor agonists.

2 esent study demonstrates that the endogenous cannabinoid receptor agonists 2-arachidonoylglycerol (2-

3 attenuated the inhibition produced by a full cannabinoid receptor agonist, (+)-[2, 3-dihydro-5-methyl

4 of several compounds as potent and selective cannabinoid receptor agonists (20, hCB(2)K(i) = 2.5 nM,

5 Because cannabinoid receptor agonists act presynaptically to inh

6 Cannabinoid receptor agonists act presynaptically to inh

7 The endogenous cannabinoid receptor agonist anandamide is present in ce

8 y examined whether systemically administered cannabinoid receptor agonists and a cannabinoid receptor

9 assessments of the physiological actions of cannabinoid receptor agonists and antagonists on adult h

10 We designed AM1241, a selective CB2 cannabinoid receptor agonist, and used it to test the hy

11 Notably, cannabinoid receptor agonists as well as inhibitors of e

12 that WIN-55,212-2 or other non-habit-forming cannabinoid receptor agonists could be developed as nove

13 esia was markedly attenuated by morphine and cannabinoid receptor agonist CP 55940.

14 Finally, the cannabinoid receptor agonists, CP55,942 and WIN55,212-2,

15 We found that administration of the cannabinoid receptor agonist CP55940 (2-[(1S,2R,5S)-5-hy

16 Neither baclofen nor a cannabinoid receptor agonist, CP55940, affected all bout

17 The cannabinoid receptor agonist, Delta(9)-tetrahydrocannabi

18 n the absence of exogenous agonists, and the cannabinoid receptor agonist desacetyllevonantradol fail

19 We tested cannabinoid receptor agonists for effects on excitatory

20 Cannabinoid receptor agonists have gained attention as p

21 Exogenous cannabinoid receptor agonists impair hippocampus-depende

22 olecule is well established as an endogenous cannabinoid receptor agonist in the brain.

23 t not the undesirable side effects of direct cannabinoid receptor agonists, indicating that FAAH may

24 ndesirable side effects observed with direct cannabinoid receptor agonists, indicating that FAAH may

25 Cannabinoid receptor agonists induced a dramatic reducti

26 We examined the effects of cannabinoid receptor agonists on forskolin-induced forma

27 pies, such as the combined use of opioid and cannabinoid receptor agonists or selective activation of

28 acute administration of the potent synthetic cannabinoid receptor agonist R-(+)-WIN 55,212-2 (WIN; 5

29 Acute application of the cannabinoid receptor agonists R(+)-methanandamide, R(+)-

30 rocannabinol (Delta(9)-THC) or the synthetic cannabinoid receptor agonist (R)-(+)-2,3-dihydro-5-methy

31 desensitized after prolonged exposure to the cannabinoid receptor agonist (R)-(+)-[2,3-dihydro-5-meth

32 We show that the cannabinoid receptor agonist, R+WIN55,212, ameliorates p

33 Based on these data we suggest that cannabinoid receptor agonists should be considered as no

34 Cannabinoid receptor agonists significantly diminish pai

35 ion of central nervous system (CNS)-excluded cannabinoid receptor agonists to test the hypothesis tha

36 exposure on the neuroprotection afforded by cannabinoid receptor agonists was also studied.

37 hibition produced by Win55212-2, a synthetic cannabinoid receptor agonist, was stereoselective and wa

38 ell EPSCs were unimpaired in the presence of cannabinoid receptor agonist when the postsynaptic membr

39 ffect were observed after treatment with the cannabinoid receptor agonist WIN 55,212-2 (0.2 mg kg(-1)

40 ffect were observed after treatment with the cannabinoid receptor agonist WIN 55,212-2 (0.2 mg kg-1 i

41 We used N1E-115 neuroblastoma cells and the cannabinoid receptor agonist WIN 55,212-2 (WIN) to exami

42 s and conductance mechanisms affected by the cannabinoid receptor agonist WIN 55,212-2 (WIN-2).

43 effects of close-arterial injections of the cannabinoid receptor agonist WIN 55,212-2 (WIN2) on uter

44 mate release is mimicked and occluded by the cannabinoid receptor agonist WIN 55,212-2, and is abolis

45 rine, nicotine, baclofen, clonidine, and the cannabinoid receptor agonist WIN 55,212.

46 Treatment of neonates with the cannabinoid receptor agonist, WIN 55,212-2 (WIN), reduce

47 The effects of the cannabinoid receptor agonist Win55,212 on Ca2+ channels

48 elf-administration (SA), using the synthetic cannabinoid receptor agonist WIN55,212-2 (WIN), in order

49 arboxamide] and mimicked and occluded by the cannabinoid receptor agonist WIN55,212-2 [(beta)-(+)-[2,

50 bolished by the exogenous application of the cannabinoid receptor agonist WIN55,212-2 [R-(+)-(2,3-dih

51 The cannabinoid receptor agonist WIN55,212-2 also reduced fi

52 n of the prototypical opioid morphine or the cannabinoid receptor agonist WIN55,212-2 produced dose-d

53 Additionally, the cannabinoid receptor agonist WIN55,212-2 suppressed IPSC

54 of corticoid-receptor antagonist RU-486 and cannabinoid-receptor agonist WIN55,212-2.

55 The cannabinoid receptor agonist WIN55212-2 (10-30 ng/side),